利民股份(002734.SZ)與昶科生物簽署戰略合作協議
格隆匯10月28日丨利民股份(002734.SZ)公佈,2024年10月21日,公司與廈門昶科生物工程有限公司(以下簡稱"昶科生物")簽署了《戰略合作協議》(以下簡稱"本協議"或"協議"),雙方將共同致力於發展以合成生物學技術、噬菌體技術為底層技術的噬菌體生物農藥,創制研發、推廣應用新型農用噬菌體生物產品。
根據協議,雙方共同創制開發新型基於噬菌體的生物農藥;噬菌體的生物農藥登記證申報;合作銷售噬菌體、天然蝦青素的微生物菌劑產品。根據雙方的未來發展戰略和資本規劃,可擇機開展共同投資新設合作項目等方面的合作,加強雙方的資源整合和戰略協同。
此協議的簽署,是公司"一主兩輔"戰略的落地實措。合作開展後,對在合成生物學方面持續發力、豐富公司產品結構、提升公司核心競爭力和持續發展能力有着構建底層基礎、實現彎道超車和推動行穩致遠的深厚意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.